Co-localization of human herpes virus 6 and tissue plasminogen activator in multiple sclerosis brain tissue

Medical Science Monitor

Volumn 11, Issue 3, 2005, Pages

  Virtanen, Jussi Oskari ^a   Zabriskie, John B ^b   Sirén, Vappu ^a   Friedman, Jacqueline E ^b   Lyons, Michael J ^b   Edgar, Mark ^c   Vaheri, Antti ^d   Koskiniemi, Marjaleena ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b ROCKEFELLER UNIVERSITY   (United States)

^c WEILL CORNELL MEDICAL CENTER   (United States)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Human herpesvirus 6; Immunohistochemistry; In situ hybridization; Multiple sclerosis; Tissue plasminogen activator

Indexed keywords

PLASMINOGEN; TISSUE PLASMINOGEN ACTIVATOR; VIRUS ANTIGEN; VIRUS RNA;

ANTIGEN DETECTION; ARTICLE; AUTOPSY; BRAIN TISSUE; CENTRAL NERVOUS SYSTEM; CHRONIC INFLAMMATION; CONTROLLED STUDY; CYTOMEGALOVIRUS; EPSTEIN BARR VIRUS; HUMAN; HUMAN HERPESVIRUS 6; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MULTIPLE SCLEROSIS; PATHOGENESIS;

ANTIGENS, VIRAL; BRAIN; CASE-CONTROL STUDIES; HERPESVIRUS 6, HUMAN; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MIDDLE AGED; MULTIPLE SCLEROSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 15944363765     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Challoner PB, Smith KT, Parker JD et al: Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. Proc Natl Acad Sci USA, 1995; 92: 7440-44
2. Friedman JE, Lyons MJ, Cu G et al: The association of the human herpesvirus-6 and MS. Mult Scler, 1999; 5: 355-62
3. Soldan SS, Fogdell-Hahn A, Brennan MB et al: Elevated serum and cerebrospinal fluid levels of soluble human herpesvirus type 6 cellular receptor, membrane cofactor protein, in patients with multiple sclerosis. Ann Neurol, 2001; 50: 486-93
4. Carroll PM, Tsirka SE, Richards WG et al: The mouse tissue plasminogen activator gene 5′ flanking region directs appropriate expression in development and a seizure-enhanced response in the CNS. Development, 1994; 120: 3173-83
5. Akenami FOT, Koskiniemi M, Mustjoki S et al: Plasma and cerebrospinal fluid activities of tissue plasminogen activator, urokinase and plasminogen activator inhibitor-1 in multiple sclerosis. Fibrinolysis & Proteolysis, 1997; 11: 109-13
6. Akenami FOT, Siren V, Wessman M et al: Tissue plasminogen activator gene expression in multiple sclerosis brain tissue. J Neurol Sci, 1999; 165: 71-76
7. Teesalu T, Kulla A, Asser T et al: Tissue plasminogen activator as a key effector in neurobiology and neuropathology. Biochem Soc Trans, 2002; 30: 183-89
8. Ascherio A, Munger KL, Lennette ET et al: Epstein-Barr virus antibodies and risk of multiple sclerosis. A prospective study. JAMA, 2001; 24: 3083-88
9. Ivanen DR, Kulminskaya AA, Shabalin KA et al: Catalytic properties of IgMs with amylolytic activity isolated from patients with multiple sclerosis. Med Sci Monit, 2004; 10(8): BR273-80
10. Gveric D, Hanemaaijer R, Newcombe J et al: Plasminogen activators in multiple sclerosis lesions: Implications for the inflammatory response and axonal damage. Brain, 2001; 124: 1978-88